Align Technology (ALGN)
(Delayed Data from NSDQ)
$267.44 USD
-4.06 (-1.50%)
Updated May 20, 2024 04:00 PM ET
After-Market: $267.41 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$267.44 USD
-4.06 (-1.50%)
Updated May 20, 2024 04:00 PM ET
After-Market: $267.41 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Reasons to Retain Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Align Technologies (ALGN) Brings New Upgrades for Oral Health
by Zacks Equity Research
Align Technologies (ALGN) introduces a series of software innovations to accelerate the digital practice transformation.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.
Align Technology's (ALGN) New Feature to Boost Patient Experience
by Zacks Equity Research
Align Technology's (ALGN) introduction of the new SmartForce feature is expected to minimize the number of attachments while maintaining predictable treatment outcomes.
Align Technologies (ALGN) Set to Acquire Cubicure GmbH
by Zacks Equity Research
Align Technologies (ALGN) announces acquisition of direct 3D printing pioneer Cubicure GmbH, backed by years of successful collaboration.
Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services
by Zacks Equity Research
Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.
Henry Schein (HSIC) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
by Zacks Equity Research
Haemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments.
Revvity (RVTY) Launches Three New Preclinical Research Systems
by Zacks Equity Research
Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.
DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany
by Zacks Equity Research
DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.
NextGen's (NXGN) Shares Rise on Potential Acquisition Rumors
by Zacks Equity Research
NextGen (NXGN) and a private equity firm, Thomas Bravo, are in advanced stages of discussion related to the acquisition of the former by the latter.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Veeva (VEEV) Rises on Robust Earnings: More Room to Grow?
by Zacks Equity Research
Veeva (VEEV) reports better-than-expected earnings and revenues for the second quarter. The raised earnings outlook for fiscal 2024 reflects optimism. Will the uptrend in shares continue?
Cooper Companies (COO) Q3 Earnings In Line, '23 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) third-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.
Patterson Companies (PDCO) Q1 Earnings In Line, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) first-quarter fiscal 2024 results reflect robust improvement in Dental Equipment sales, value-added services and Animal Health segment.
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Align Technology (ALGN) Down 9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Earnings Estimates Rising for Align Technology (ALGN): Will It Gain?
by Zacks Equity Research
Align Technology (ALGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Align Technology (ALGN) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?
Here's How Much a $1000 Investment in Align Technology Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Align (ALGN) Rides on Growing Invisalign Sales, New Alliances
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.